Please assess the completion status of the following clinical trial:

Trial Title: A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants aged greater than or equal to 21 and less than 65 years at the time of obtaining written informed consent~2. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version and have both of the following conditions which are persistent for more than or equal to 4 weeks before the start of observation period:~   * Sleep latency of more than or equal to 30 minutes for more than or equal to 3 days a week~  * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week~3. Participants who meet both of the following based on polysomnogram (PSG) in observation period:~   * Objective sleep latency of more than or equal to 20 minutes for 2 consecutive PSG days~  * Objective total sleep time of less than or equal to 420 minutes for 2 consecutive PSG days, or objective wake time during sleep of more than or equal to 20 minutes for 2 consecutive PSG days~Exclusion Criteria:~1. Participants with comorbid primary sleep disorders (e.g., circadian rhythm disorder, restless limb syndrome, periodic limb movement disorder, sleep apnea syndrome), other than primary insomnia.~2. Participants with insomnia caused by pharmacological actions (drug-induced insomnia).~3. Participants with comorbid sleep disorder associated with other disease(s) such as psychiatric and/or physical disease(s).~4. Participants with a complication of psychiatric disorders in Axis I or personality disorder in Axis II defined in DSM-IV-TR Japanese version.~5. Participants with organic mental disorder.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone 1 mg (Type: EXPERIMENTAL): None
- Eszopiclone 2 mg (Type: EXPERIMENTAL): None
- Eszopiclone 3 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Zolpidem Tartrate 10 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).